US Bancorp DE Sells 31,254 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
US Bancorp DE Sells 31,254 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
US Bancorp DE cut its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 59.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,402 shares of the company's stock after selling 31,254 shares during the quarter. US Bancorp DE's holdings in Maravai LifeSciences were worth $547,000 as of its most recent SEC filing.
根据US Bancorp DE最近提交给美国证券交易委员会的Form 13F文件，该公司第三季度将其在Maravai LifeSciences Holdings，Inc.(纳斯达克代码：MRVI-GET Rating)的头寸削减了59.4%。该机构投资者在本季度出售了31,254股后，持有该公司21,402股股票。截至最近提交的美国证券交易委员会申报文件，US Bancorp DE持有的Maravai LifeSciences股份价值547,000美元。
Other hedge funds and other institutional investors have also made changes to their positions in the company. Massachusetts Financial Services Co. MA grew its stake in Maravai LifeSciences by 41.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 12,691,171 shares of the company's stock valued at $360,556,000 after buying an additional 3,726,068 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Maravai LifeSciences by 4.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,530,561 shares of the company's stock valued at $100,303,000 after buying an additional 135,961 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of Maravai LifeSciences by 11.4% during the 2nd quarter. Clearbridge Investments LLC now owns 2,707,875 shares of the company's stock worth $76,931,000 after purchasing an additional 277,260 shares in the last quarter. Artemis Investment Management LLP grew its position in shares of Maravai LifeSciences by 10.8% during the 3rd quarter. Artemis Investment Management LLP now owns 2,476,728 shares of the company's stock worth $63,262,000 after purchasing an additional 242,162 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Maravai LifeSciences by 105.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,875,000 shares of the company's stock worth $53,269,000 after purchasing an additional 961,800 shares in the last quarter. 48.67% of the stock is owned by institutional investors.
其他对冲基金和其他机构投资者也改变了他们在该公司的头寸。第二季度，马云在Maravai LifeSciences的持股增加了41.6%。马云现在持有该公司12,691,171股股票，价值360,556,000美元。马云在上个季度又购买了3,726,068股。第二季度，摩根大通在Maravai LifeSciences的持股增加了4.0%。摩根大通目前持有该公司3,530,561股股票，价值100,303,000美元，上一季度又购买了135,961股。ClearBridge Investments LLC在第二季度将其在Maravai LifeSciences的股票头寸增加了11.4%。ClearBridge Investments LLC现在拥有该公司2,707,875股股票，价值76,931,000美元，上个季度又购买了277,260股。Artemis Investment Management LLP在第三季度将其在Maravai LifeSciences的股票头寸增加了10.8%。Artemis Investment Management LLP现在拥有该公司2,476,728股股票，价值63,262,000美元，上个季度又购买了242,162股。最后，复兴科技有限公司在第二季度将其在马拉威生命科学公司的股票持有量增加了105.3%。复兴科技有限责任公司现在拥有1,875,000股该公司股票，价值53,269,000美元，上个季度又购买了961,800股。48.67%的股份由机构投资者持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of brokerages have issued reports on MRVI. Bank of America lowered shares of Maravai LifeSciences from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $32.00 to $17.00 in a research report on Thursday, November 3rd. Morgan Stanley decreased their target price on shares of Maravai LifeSciences from $35.00 to $32.00 and set an "overweight" rating on the stock in a research report on Friday, November 4th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Maravai LifeSciences in a report on Tuesday, December 13th. They set a "buy" rating and a $25.00 price target for the company. Credit Suisse Group cut their price target on shares of Maravai LifeSciences from $34.00 to $26.00 and set an "outperform" rating for the company in a report on Thursday, November 3rd. Finally, KeyCorp cut their price target on shares of Maravai LifeSciences from $35.00 to $28.00 and set an "overweight" rating for the company in a report on Thursday, November 3rd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.00.
多家券商发布了关于MRVI的报告。在11月3日周四的一份研究报告中，美国银行将Maravai LifeSciences的股票评级从买入下调至中性，并将该股的目标价从32.00美元下调至17.00美元。摩根士丹利在11月4日(周五)的一份研究报告中将Maravai LifeSciences的股票目标价从35.00美元下调至32.00美元，并对该股设定了“增持”评级。德意志银行Aktiengesellschaft在12月13日(星期二)的一份报告中对Maravai LifeSciences的股票进行了报道。他们为该公司设定了“买入”评级和25.00美元的目标价。瑞士信贷集团在11月3日周四的一份报告中将Maravai LifeSciences的股票目标价从34.00美元下调至26.00美元，并为该公司设定了“跑赢大盘”的评级。最后，KeyCorp在11月3日周四的一份报告中将Maravai LifeSciences的股票目标价从35.00美元下调至28.00美元，并为该公司设定了“增持”评级。两名分析师对该股的评级为持有，六名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，该公司目前的共识评级为“适度买入”，共识目标价为23.00美元。
Maravai LifeSciences Price Performance
Maravai LifeSciences性价比
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.05. The firm had revenue of $191.26 million during the quarter, compared to the consensus estimate of $193.83 million. Maravai LifeSciences had a net margin of 26.29% and a return on equity of 69.19%. Research analysts predict that Maravai LifeSciences Holdings, Inc. will post 1.79 earnings per share for the current fiscal year.
马拉威生命科学(纳斯达克：MRVI-GET Rating)上一次发布季度收益报告是在11月2日(周三)。该公司公布本季度每股收益(EPS)为0.37美元，比市场普遍预期的0.32美元高出0.05美元。该公司本季度营收为1.9126亿美元，而市场普遍预期为1.9383亿美元。Maravai LifeSciences的净利润率为26.29%，股本回报率为69.19%。研究分析师预测，Maravai LifeSciences Holdings，Inc.本财年每股收益将达到1.79美元。
Maravai LifeSciences Company Profile
Maravai LifeSciences公司简介
(Get Rating)
(获取评级)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Maravai LifeSciences控股公司是一家生命科学公司，提供能够在美国和国际上开发药物疗法、诊断、新型疫苗和支持人类疾病研究的产品。该公司的产品涉及生物制药开发的关键阶段，包括用于诊断和治疗应用的核酸、在生物制药产品生产过程中检测杂质的基于抗体的产品，以及检测各种组织中蛋白质表达的产品。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取StockNews.com关于Maravai LifeSciences(MRVI)的研究报告
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车？
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票：在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating).
想看看其他对冲基金持有MRVI吗？访问HoldingsChannel.com获取马拉维生命科学控股公司(纳斯达克代码：MRVI-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Maravai生命科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Maravai LifeSciences和相关公司的最新新闻和分析师评级的每日简要摘要。